Skip Nav Destination
1-12 of 12
Clin Sci (Lond) (1999) 97 (6): 689–695.
Published: 15 November 1999
... their use as indicators of cardiac function in routine clinical practice. Inhibitors such as aprotinin are routinely added in the blood collection process, but may provide no benefit in sample collection and routine clinical practice. We assessed the stability of BNP, ANP and N-terminal ANP in blood samples...
Clin Sci (Lond) (1998) 94 (5): 505–509.
Published: 01 May 1998
...N. L. Bruda; B. J. Hurlbert; G. E. Hill 1. Cardiopulmonary bypass is associated with an increase in nitric oxide concentrations, and plasma levels of tumour necrosis factor and interleukin-1. Aprotinin, a serine protease inhibitor, commonly used during cardiopulmonary bypass to reduce blood loss...
Rana Rustom, J. Steve Grime, Michael Costigan, Paul Maltby, Anthony Hughes, Alan Shenkin, Mair Critchley, J. Michael Bone
Clin Sci (Lond) (1998) 94 (4): 425–430.
Published: 01 April 1998
... renal tubular protein catabolism or markers of tubular injury before and after lisinopril. We developed a method to allow such studies, and found increased tubular catabolism of 99m Tc-labelled aprotinin (Trasylol) in patients with nephrotic range proteinuria which was associated with increased ammonia...
Clin Sci (Lond) (1994) 87 (3): 329–335.
Published: 01 September 1994
... in cirrhosis, and reduced systemic vascular resistance has been suggested as a trigger to renal sodium retention in this disease. We investigated the effect of aprotinin, a protease inhibitor which binds to plasma kallikrein, on systemic haemodynamics and renal function in patients with hepatic cirrhosis...
Clin Sci (Lond) (1993) 85 (6): 733–736.
Published: 01 December 1993
...R. Rustom; J. S. Grime; P. Maltby; H. R. Stockdale; M. J. Jackson; M. Critchley; J. M. Bone 1. The new method developed to measure renal tubular degradation of small filtered proteins in patients with normal renal function, using radio-labelled aprotinin (Trasylol) (R. Rustom, J. S. Grime, P...
Clin Sci (Lond) (1993) 84 (2): 231–235.
Published: 01 February 1993
...R. Rustom; J. S. Grime; P. Maltby; H. R. Stockdale; M. Critchley; J. M. Bone 1. The novel method recently developed to measure renal tubular degradation of filtered proteins in man using radiolabelled aprotinin (Trasylol) has been modified to allow the fate and the significance of the renal...
Clin Sci (Lond) (1992) 83 (3): 289–294.
Published: 01 September 1992
...R. Rustom; S. Grime; P. Maltby; H. R. Stockdale; M. Critchley; J. M. Bone 1. A method has been developed to measure the renal tubular degradation of small filtered proteins in man using radiolabelled aprotinin (Trasylol), a 6500 Da cationic polypeptide. 2. Aprotinin (0.5 or 5.0 mg) was labelled...
Clin Sci (Lond) (1992) 83 (3): 295–299.
Published: 01 September 1992
...R. Rustom; P. Maltby; J. S. Grime; H. R. Stockdale; M. Critchley; J. M. Bone 1. Aprotinin (Trasylol) is a cationic 6500 Da polypeptide that inhibits proteolytic enzymes, and when labelled with 99m Tc it is a reproducible marker for the renal tubular turnover of small filtered proteins in man...
Clin Sci (Lond) (1982) 62 (4): 361–366.
Published: 01 April 1982
... structural vascular changes persisted for much longer. 3. Blood pressure in this model of hypertension was not affected by a 15 h infusion of either indomethacin or aprotinin. 4. The pattern of fall in blood pressure after removal of the clip was similar when animals were infused with either indomethacin...
Clin Sci (Lond) (1980) 59 (s6): 129s–132s.
Published: 01 December 1980
...A. Overlack; K. O. Stumpe; M. Kuhnert; I. Heck 1. The effect of aprotinin-induced blockade of the kallikrein-kinin system on haemodynamic and biochemical responses to converting enzyme inhibition by SQ 14 225 was evaluated in 26 patients with essential hypertension. 2. SQ 14 225 lowered blood...
Clin Sci (Lond) (1979) 57 (s5): 255s–258s.
Published: 01 December 1979
...T. C. Lee; T. Kushiro; J.-P. Gassia; J.-P. Girolami; A. N. Lupu; M. H. Maxwell 1. The acute effects of the kallikrein inhibitor aprotinin (498 ki.u./min), and the kininase II inhibitor SQ 14 225 (250 μg), given intravenously during saralasin-induced angiotensin blockade, were studied in conscious...
Clin Sci (Lond) (1979) 56 (6): 547–553.
Published: 01 June 1979
...H. J. Kramer; T. Moch; L. Von Sicherer; R. Düsing 1. Aprotinin, a potent kallikrein inhibitor, was given to conscious rats with and without expansion of the extracellular fluid volume with isotonic saline. 2. In noa-expanded rats aprotinin had no effect on arterial pressure, glomerular filtration...